Supernus Pharmaceuticals
SUPN
333 hedge funds and large institutions have $2.84B invested in Supernus Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 114 increasing their positions, 112 reducing their positions, and 33 closing their positions.
91% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 33
10% more call options, than puts
Call options by funds: $5.9M | Put options by funds: $5.35M
7% more funds holding
Funds holding: 310 → 333 (+23)
3% more capital invested
Capital invested by funds: $2.76B → $2.84B (+$82.1M)
2% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 112
3.28% less ownership
Funds ownership: 102.9% → 99.62% (-3.3%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| 1 |
Millennium Management
New York
|
+$112M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.5M |
| 3 |
Morgan Stanley
New York
|
+$15.8M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$13.2M |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
+$13.2M |
Top Sellers
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$121M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$60.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$46.9M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$28.5M |
| 5 |
Goldman Sachs
New York
|
-$24.4M |
SUPN Hedge Fund Activity: Q4 2025 in Review
333 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2025, worth a combined $2.84B — up 3% from $2.76B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new SUPN positions and 33 closed out — a net gain of 30 holders — while 114 added to existing stakes and 112 trimmed.
The largest buyer was Millennium Management, adding an estimated $112M. The largest seller was Macquarie Group, exiting entirely with an estimated $121M sold.
- 333 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2025, up from 310 in Q3 2025.
- Funds reported $2.84B of Supernus Pharmaceuticals stock for Q4 2025, up 3% quarter-over-quarter.
- 63 funds opened new Supernus Pharmaceuticals positions in Q4 2025 and 33 closed out, a net change of +30 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2025 was Millennium Management, an estimated $112M added.
- The largest Supernus Pharmaceuticals seller in Q4 2025 was Macquarie Group, an estimated $121M sold.
Based on aggregated 13F filings for Q4 2025.